Related Experiment Video
Updated: Jun 21, 2026

Cholesterol Efflux Assay
Published on: March 6, 2012
Regulation of reverse cholesterol transport and clinical implications
1Preventive Cardiology/Lipid Research Center, University of Pennsylvania Health System, Philadelphia, Pennsylvania 19104, USA. rader@mail.med.upenn.edu
Insights
High-density lipoprotein (HDL) cholesterol and apolipoprotein A-I protect against atherosclerosis by promoting reverse cholesterol transport. New developments in this process have significant clinical implications for cardiovascular disease.
Area of Science:
- Cardiovascular Science
- Lipid Metabolism
- Atherosclerosis Research
Background:
- Plasma levels of high-density lipoprotein (HDL) cholesterol and apolipoprotein A-I are inversely correlated with atherosclerotic cardiovascular disease.
- Low HDL and apolipoprotein A-I levels are associated with metabolic syndrome, insulin resistance, and type 2 diabetes.
- Apolipoprotein A-I overexpression in animal models reduces atherosclerosis progression and induces regression, suggesting a direct protective role.
Purpose of the Study:
- To review new developments in the regulation of reverse cholesterol transport.
- To discuss the clinical implications of these advancements in reverse cholesterol transport.
Main Methods:
- Review of recent scientific literature on reverse cholesterol transport.
- Analysis of studies investigating apolipoprotein A-I function and regulation.
- Examination of clinical data related to HDL cholesterol and cardiovascular outcomes.
Main Results:
- Apolipoprotein A-I directly inhibits atherosclerosis, primarily through promoting cholesterol efflux from macrophages.
- Reverse cholesterol transport is a key mechanism by which apolipoprotein A-I exerts its protective effects.
- Emerging research highlights novel regulatory pathways influencing reverse cholesterol transport.
Conclusions:
- Apolipoprotein A-I plays a crucial role in preventing and potentially reversing atherosclerosis.
- Understanding the regulation of reverse cholesterol transport offers new therapeutic strategies for cardiovascular disease.
- Further research into reverse cholesterol transport mechanisms is warranted for clinical application.
Abstract:
Plasma levels of high-density lipoprotein (HDL) cholesterol and its major protein, apolipoprotein A-I, are inversely correlated with the incidence of atherosclerotic cardiovascular disease. Low HDL cholesterol and apolipoprotein A-I levels often are found in association with other cardiovascular risk factors, including the metabolic syndrome, insulin resistance, and type 2 diabetes mellitus. However, overexpression of apolipoprotein A-I in animals has been shown to reduce progression and even induce regression of atherosclerosis, indicating that apolipoprotein A-I is directly protective against atherosclerosis. A major mechanism by which apolipoprotein A-I inhibits atherosclerosis may be by promoting cholesterol efflux from macrophages and returning it to the liver for excretion, a process termed reverse cholesterol transport. This article focuses on new developments in the regulation of reverse cholesterol transport and the clinical implications of those developments.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Lipids: Dietary Sources and Requirements
Cholesterol: Significance and Regulation
Considering cholesterol and...
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management

